Ovid Therapeutics Analyst Ratings
H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $3
Buy Rating Affirmed for Ovid Therapeutics on Promising Safety Profile and Robust Pipeline Progress
B.Riley Financial Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Cuts Target Price to $3
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Hold Rating
Oppenheimer Sticks to Their Hold Rating for Ovid Therapeutics (OVID)
BTIG Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5
Ovid Therapeutics Analyst Ratings
H.C. Wainwright Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)
H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $3
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Cuts Target Price to $4
Wedbush Remains a Buy on Ovid Therapeutics (OVID)
BTIG Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5
Ladenburg Thalmann Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $2
Buy Rating Justified by Ovid Therapeutics' Clinical Progress and Strong Financials
The Latest Analyst Ratings For Ovid Therapeutics
Ovid Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $3 Price Target
Buy Rating Affirmed for Ovid Therapeutics on Advisory Expansion and Promising Epilepsy Drug Prospects